Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $22.57 Average Target Price from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has been given an average rating of “Moderate Buy” by the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $22.57.

A number of equities research analysts recently commented on the company. JMP Securities lifted their price objective on Acrivon Therapeutics from $14.00 to $17.00 and gave the stock a “market outperform” rating in a research note on Thursday, April 25th. Piper Sandler boosted their target price on Acrivon Therapeutics from $26.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, April 25th. LADENBURG THALM/SH SH cut Acrivon Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, April 29th. BMO Capital Markets restated an “outperform” rating and issued a $25.00 price target on shares of Acrivon Therapeutics in a report on Wednesday, May 15th. Finally, HC Wainwright boosted their price target on Acrivon Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, May 14th.

Institutional Trading of Acrivon Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Exchange Traded Concepts LLC raised its holdings in Acrivon Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 13,289 shares of the company’s stock worth $65,000 after acquiring an additional 3,370 shares in the last quarter. Vanguard Group Inc. raised its holdings in Acrivon Therapeutics by 6.6% during the first quarter. Vanguard Group Inc. now owns 507,185 shares of the company’s stock worth $3,626,000 after acquiring an additional 31,208 shares in the last quarter. American International Group Inc. raised its holdings in Acrivon Therapeutics by 39.2% during the first quarter. American International Group Inc. now owns 6,016 shares of the company’s stock worth $43,000 after acquiring an additional 1,695 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new stake in Acrivon Therapeutics during the first quarter worth about $378,000. Institutional investors own 71.62% of the company’s stock.

Acrivon Therapeutics Stock Performance

NASDAQ ACRV opened at $7.16 on Thursday. Acrivon Therapeutics has a 52 week low of $3.19 and a 52 week high of $13.50. The stock has a fifty day moving average of $7.46 and a 200-day moving average of $6.32. The stock has a market capitalization of $221.10 million, a P/E ratio of -2.49 and a beta of 0.86.

Acrivon Therapeutics (NASDAQ:ACRV) last announced its quarterly earnings data on Tuesday, May 14th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.16. Equities research analysts forecast that Acrivon Therapeutics will post -2.47 earnings per share for the current fiscal year.

About Acrivon Therapeutics

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.